Tradestie Institutional Equity Comparison Engine
EVMN vs AUTL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AUTL at N/M Forward P/E and -159.3% operating margin (+94.6% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against AUTL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVMN N/M vs AUTL N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin 0.0% vs -159.3% ยท YoY +0.0% vs +94.6%
Momentum & Technical Winner
EVMN
1Y -61.0% vs -10.9% ยท 52W Pos 8% vs 5%
Options & Structure Winner
EVMN
SURGE (53rd %ile IV) vs UNCLASSIFIED (<1st %ile IV)
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
AUTL
NASDAQ
Autolus Therapeutics plc American Depositary Share
Biological Products, (No Disgnostic Substances)
$1.14
-2.56% 1D
Market Cap
$311.4M
1M Return
-28.75%
1Y Return
-10.94%
Forward P/E
N/M
Unified AI Score
40.4 / 100
SELL
Tech 25.0
Fund 42.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVMN -61.03%
AUTL -10.94%
Spread: +50.09 pp (AUTL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EVMN TTM Op. Margin: 0.0%
AUTL TTM Op. Margin: -159.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVMN vs AUTL. Trailing 12-month operating profitability (EVMN 0.0% vs AUTL -159.3%) and valuation multiples (EVMN N/M vs AUTL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVMN | AUTL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $315.5M | $311.4M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +94.6% | Higher Growth | AUTL |
| Operating Margin (TTM) Profitability | 0.0% | -159.3% | Higher Margin | EVMN |
| Net Profit Margin Profitability | 0.0% | -186.4% | Higher Margin | EVMN |
| Return on Equity (ROE) Capital Efficiency | -69.5% | -174.9% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 8% ($5โ$33) | 5% ($1โ$3) | Stronger Trend | EVMN |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 118% Vol | 1.66ฮฒ ยท 55% Vol | Lower Realized Risk | AUTL |
| Unified Institutional Score Composite Signal | 30.0 / 100 (SELL) | 40.4 / 100 (SELL) | Higher Composite | AUTL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVMN vs AUTL Buy Guide
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
AUTL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVMN nor AUTL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.